To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must be at least 1 year of age and no older than age 75.
- Patients must have achieved remission after receiving a T cell-depleted allogeneic stem cell transplant for AML or MDS.
- Patients should enter the study 60 to 120 days after their transplant.
For more information and to inquire about eligibility for this study, please contact Dr. Hugo Castro-Malaspina at 212-639-8197.